Financial Report -Pfizer

Pfizer

1Q Revenues: $12.0 billion (-8%)
1Q Earnings: $3.4 billion (-12%)
Comments: Biopharma revenues were up 11% to $10.0 billion. Eliquis sales were up 29% to $1.3 billion in the quarter. Vyndaqel sales were $231 million in the quarter compared to $41 million in 1Q19. Ibrance sales were up 10% to $1.2 billion. Prevenar 13 sales were down 2% to $1.5 billion. Inlyta sales were $169 million in the quarter compared to $73 million in 1Q19. Xeljanz sales were up 7% to $451 million. Xtandi sales were $209 million, up 25%. Enbrel sales (Outside the U.S. and Canada) were $347 million, down 23%. Upjohn sales were down 37% to $2.0 billion primarily due to significant volume declines for Lyrica in the U.S. due to multi-source generic competition. Upjohn revenues in China declined 41% operationally, driven by declines from Lipitor and Norvasc. Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan. Acquisition of Pfizer’s Consumer Healthcare business by the GSK Consumer Healthcare joint venture (JV) was completed during 2019, impacting financial results.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.